pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
CRISPR/Cas9 · news · pharmadog
← back to CRISPR/Cas9
News · CRISPR/Cas9
130
stories
Aug 4, 26
STAT+: Startup promising to scale custom CRISPR therapies abruptly scraps plans
stat
Aug 3, 26
Biotech leaders call for streamlining of INDs as FDA’s Trialblazer rolls out
biospace
Jul 28, 26
Apnimed eyes up to $160M IPO to prep for sleep apnea drug launch
biospace
Jul 28, 26
STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD
stat
Jul 27, 26
Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO
biopharma dive
Jul 27, 26
Sarepta turns to Michael Severino as CEO, looking to move past recent turmoil
endpoints
Jul 24, 26
Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech
biospace
Jul 24, 26
STAT+: Fatal gene-editing trial in China raises ethics and oversight questions
stat
Jul 24, 26
Michael Ehlers joins Formation Bio to lead R&D; Black Diamond co-founder dies at 67
endpoints
Jul 24, 26
Gene editor Scribe starts second-half IPO spree with $129M listing
endpoints
Jul 24, 26
Scribe secures $129M in a rare gene editing IPO
biopharma dive
Jul 24, 26
Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds
fiercebiotech
Jul 22, 26
6 companies hiring in Cambridge now
biospace
Jul 20, 26
Scribe's $96M IPO; Scholar Rock awaits site classification for apitegromab
endpoints
Jul 20, 26
Genetic medicine luminaries launch new center for personalized therapies
fiercebiotech
Jul 20, 26
Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic meds
fiercebiotech
Jul 17, 26
STAT+: Can ultrasound unlock the power of gene therapy? A startup makes big claims
stat
Jul 15, 26
Nobel Laureate Jennifer Doudna enters AI protein design arena
fiercebiotech
Jul 13, 26
STAT+: Dementia study replicates promising outcomes following risk-reduction strategies
stat
Jul 13, 26
STAT+: All eyes on data on Biogen’s tau therapy
stat
Jul 13, 26
STAT+: A breakthrough in pancreatic cancer has experts excited — and braced for what’s to come
stat
Jul 12, 26
STAT+: Tau in the spotlight at Alzheimer’s conference
stat
Jul 10, 26
STAT+: Roche ends Huntington’s gene-silencing programs
stat
Jul 10, 26
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
biopharma dive
Jul 10, 26
FDA quietly pushes back deadline on electric shock ban
stat
Jul 10, 26
New York boys club has a time-tested recipe to protect members’ mental health
stat
Jul 9, 26
ARPA-H bookmarks $160M for custom gene editing treatments. Is it enough?
endpoints
Jul 9, 26
Outbreak of diarrhea-causing parasite grows to more than 1,000 cases
stat
Jul 9, 26
STAT+: ARPA-H launches $160 million effort to develop custom gene editing drugs
stat
Jul 8, 26
Prime Medicine wins spat with Beam Therapeutics over AATD candidate
endpoints
← prev
page 3 of 5
next →
